09688 News
Zai Lab to Participate in 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Zai Lab Receives NMPA Approval for COBENFY to Treat Schizophrenia
UBS Maintains Buy Rating on ZAI LAB, Lowers Target Price to HKD 20.1
Zai Lab Updates Three Medicines in China's National Reimbursement Drug List
<Research>UBS Identifies Chinese Stocks with Greatest Potential for FY26 Earnings Growth (Table)
BofAS Reduces ZAI LAB (09688.HK) Price Target to $19.92 Due to Sales Challenges for Core Products
Citi Lowers ZAI LAB (09688.HK) Price Target to US$58 Following Disappointing 3Q Revenue Results
ZAI LAB Falls 8% to Over One-Year Low Following Disappointing 3Q Results
09688 Events
No data
09688 Monitor News
No data
09688 Earnings Analysis